Evidence map›Paper›PMID 39148307›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2024

Establishment of a Mesoamerican-Caribbean South-South Research Platform: Challenges in the Meriva (Curcuminoids) Gastric Cancer Chemoprevention Trial.

Eleazar E Montalvan-Sanchez, Jessica Hernandez-Marrero, Dalton A Norwood, María González-Pons, Ricardo L Dominguez, Luz M Rodriguez, Ellen Richmond, Paul J Limburg, Marcia Cruz-Correa, Douglas R Morgan

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase IIMulticenter Study
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02782949 (Randomized, Double-Blind, Placebo-Controlled Trial of Meriva®), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02782949 phase2active not recruitingnot on this map

Randomized, Double-Blind, Placebo-Controlled Trial of Meriva® (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2017 to 2027Enrolled50ConditionsChronic Atrophic Gastritis, Gastric CarcinomaArmsCurcumin, Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eleazar E Montalvan-SanchezDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0000-0002-7178-0724
Jessica Hernandez-MarreroUPR School of Medicine, San Juan, Puerto Rico.ORCID 0000-0003-2192-5216
Dalton A NorwoodHospital de Occidente, Ministry of Health, Copan, Honduras.ORCID 0000-0001-5408-560X
María González-PonsUPR School of Medicine, San Juan, Puerto Rico.ORCID 0000-0002-3694-0534
Ricardo L DominguezHospital de Occidente, Ministry of Health, Copan, Honduras.ORCID 0000-0001-5171-4415
Luz M RodriguezDivision of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-2119-6124
Ellen RichmondDivision of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-5855-5047
Paul J LimburgMayo Clinic Rochester, Rochester, Minnesota.ORCID 0000-0002-2428-5675
Marcia Cruz-CorreaUPR School of Medicine, San Juan, Puerto Rico.ORCID 0000-0001-8147-7457
Douglas R MorganDepartment of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama.ORCID 0000-0002-1136-0963

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
UPR/MDACC Partnership for Excellence in Cancer Research(Parent Grant U54 CA096297)U54CA096297 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI SHARON Hermes GIORDANO, REYNOLD Eugenio LOPEZ-ENRIQUEZ · 2002 to 2026
$36.9M
Hispanics in Research Capability: SoHP & SOM Partnership (HIREC)S21MD001830 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI ELIAS BONETA, AUGUSTO R, ESTAPE, ESTELA S · 2005 to 2010
$30.0M
UPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHARON Hermes GIORDANO · 2002 to 2026
$23.8M
TECHNOLOGIES AND RESOURCES FOR CORE LABORATORIESU54MD007587 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI LUCIANO, CARLOS A., WOJNA, VALERIE · 2012 to 2018
$23.2M
Project 3 - Molecular Signatures of Gastric Carcinogenesis in the Host Response to H. pyloriP01CA028842 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILSON, KEITH T. · 1985 to 2019
$15.8M
UPR School of Medicine Endowed Health Services Research*S21MD000242 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI FRONTERA, WALTER R · 2002 to 2004
$15.0M
Hispanic Clinical and Translational Research Education and Career Development ProgramR25MD007607 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Karen G. Martinez Gonzalez, Barbara Segarra-Vazquez · 2012 to 2026
$7.4M
Targeted chemoprevention of gastric carcinogenesis in high risk populationsR01CA190612 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MORGAN, DOUGLAS, WILSON, KEITH T. · 2014 to 2018
$3.0M
UPR School of Medicine Program for Research ExcellenceS21MD000138 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI JOGLAR, FRANCISCO M · 2002 to 2002
$2.9M
NCI NIH HHS P01 CA028842NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA190612NCI NIH HHS U54 CA096297NCI NIH HHS U54 CA096300NIMHD NIH HHS R25 MD007607NIMHD NIH HHS S21 MD000138NIMHD NIH HHS S21 MD000242NIMHD NIH HHS S21 MD001830NIMHD NIH HHS U54 MD007587
6 · The paper itself

Abstract

Gastric adenocarcinoma (GAC) is the fourth leading global cause of cancer mortality and leading infection-associated cancer. High-incidence regions of GAC include Latin America and Eastern Asia. Immigrants from high-incidence regions maintain their GAC risk. GAC is a major U.S. cancer disparity, and its incidence rates are 2 to 10 times higher in non-White populations. Emerging guidelines recommend 3-year surveillance endoscopy for patients with high-risk gastric premalignant conditions (GPMC). Clinical trials of GPMC chemoprevention agents are lacking. We conducted a NCI Division of Cancer Prevention-funded, phase II placebo-controlled chemoprevention trial in patients with GPMCs (atrophic gastritis and intestinal metaplasia) with a highly bioavailable preparation of curcuminoids (Meriva). The trial sites in Puerto Rico and rural Honduras had important characteristics: (i) representative Caribbean and Mesoamerican populations, linked to large U.S. immigrant populations; (ii) high prevalence of Helicobacter pylori infection and GPMCs; (iii) the absence of turmeric and curcuminoids in local diets; and (iv) proven bidirectional collaboration with U.S. academic institutions. H. pylori-negative patients with GPMCs were randomized to the study drug (500 mg po bid) or placebo for 180 days (NCT02782949), with primary outcomes based upon histologic parameters. Principal study challenges included (i) an international regulatory environment; (ii) research infrastructure strengthening, particularly in Central America; (iii) participant recruitment in Honduras, wherein only 10% to 15% are H. pylori negative; (iv) the COVID-19 pandemic; and (v) natural disasters (three hurricanes). There were no losses to follow-up related to the pandemic or natural disasters. In conclusion, the south-south partnership provides a model for chemoprevention and translational studies in Latino populations with prevalent cancers, such as GAC.

Indexed as

Stomach NeoplasmsAdenocarcinomaAdultAgedChemopreventionCurcuminFemaleGastritis, AtrophicHelicobacter InfectionsHelicobacter pyloriHondurasHumansMaleMiddle AgedPrecancerous ConditionsPuerto RicoCurcumin

Identifiers

PMID39148307
PMCPMC12286413

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.